Publications scientifiques
Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).
-
Fibrose pulmonaire - FPI
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine
American Journal of Respiratory and Critical Care Medicine 210, nᵒ 4 (août 2024): 401‑23.
-
Pneumopathies interstitielles diffuses (PID)
Diffuse Lung Diseases Ascribed to Drugs: A Nationwide Observational Study over 37 Years Using the French Pharmacovigilance Database
The European Respiratory Journal 65, nᵒ 2 (février 2025): 2400756.
-
Pneumopathies interstitielles diffuses (PID)
Population Pharmacokinetics of Mycophenolate in Patients Treated for Interstitial Lung Disease (EVER-ILD Study)
Fundamental & Clinical Pharmacology 38, nᵒ 5 (juin 2024): 1008‑16.
-
Fibrose pulmonaire - FPI
Worsening Dyspnoea as a Predictor of Progression of Pulmonary Fibrosis
European Respiratory Journal 64, nᵒ 4 (octobre 2024)
-
Pneumopathies interstitielles diffuses (PID)
Towards the Adoption of Quantitative Computed Tomography in the Management of Interstitial Lung Disease
European Respiratory Review 33, nᵒ 171 (mars 2024).
-
Pneumopathies interstitielles diffuses (PID)
Interstitial Lung Disease Associated with Anti-Ku Antibodies: A Case Series of 19 Patients
Journal of Clinical Medicine 14, nᵒ 1 (janvier 2025): 247.
-
Pneumopathies interstitielles diffuses (PID)
Value of Lung Ultrasonography for Screening Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Rheumatology (Oxford, England), mars 2025, keaf133.
-
Pneumopathies interstitielles diffuses (PID)
Interstitial Lung Disease Associated with Systemic Sclerosis
Seminars in Respiratory and Critical Care Medicine 45, nᵒ 3 (juin 2024): 342‑64.
-
Pneumopathies interstitielles diffuses (PID)
Usefulness of monitoring mycophenolic acid exposure in systemic sclerosis-related interstitial lung disease: a retrospective cohort study
BMC Pulmonary Medicine 24, nᵒ 1 (octobre 2024): 537.
-
Pneumopathies interstitielles diffuses (PID)
Rituximab and Mycophenolate Mofetil in Interstitial Lung Disease (EVER-ILD): 1-Year Follow-up Results of a Randomised Controlled Trial
The European Respiratory Journal 64, nᵒ 3 (septembre 2024): 2401368.